A seven-day, extended-release version of buprenorphine — a treatment for opioid use disorder (OUD) that can reduce opioid use and overdose deaths — is safe and effective for people with OUD ...

Extended-release 7-day injectable buprenorphine was safe and tolerable for most patients who had minimal-to-mild opioid withdrawal, a nonrandomized trial found. Among 100 adult patients with ...

Please provide your email address to receive an email when new articles are posted on . The study included 227 individuals with OUD given CAM2038 either on weekly or monthly basis. The treatment was ...

More than 15 years ago, Yale's Gail D'Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.

A University of Calgary-led international research team has identified a genetic factor that may explain why people respond so differently to opioid pain medications, and why some individuals face ...

Hospitals have faced mounting pressure in recent years to find better treatments for patients who are in the throes of opioid withdrawal. The challenge of safely managing these patients' symptoms is ...

Precipitated withdrawal may result from starting certain medications to treat opioid use disorder (OUD) too soon after using opioids. Typically, withdrawal symptoms occur when a person stops using ...

An existing drug currently used to treat glaucoma, altitude sickness, and seizures may also have the potential to prevent ...